Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) – Pipeline Review, H2 2017’, provides in depth analysis on Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Oncology under development targeting Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Overview 6

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Therapeutics Assessment 12

Assessment by Mechanism of Action 12

Assessment by Route of Administration 14

Assessment by Molecule Type 16

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Drug Profiles 17

Bryostatin-1 - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

VMD-1201 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

VMD-2202 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Dormant Products 29

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Discontinued Products 30

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Product Development Milestones 31

Featured News & Press Releases 31

Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017 31

Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting 32

May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease 32

Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017 33

Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia 34

Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease 34

Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead 35

Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes 36

Jun 13, 2016: Neurotrope's Chief Scientific Officer Dr. Daniel Alkon Presents at the Gordon Conference: Drugs That Target Common Mechanisms for Synaptic Restoration in Mental Retardation and Alzheimer's Disease 36

Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model 37

Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease 37

Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease 38

Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer’s Disease 38

Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference 39

Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease 39

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 16

Dormant Projects, H2 2017 29

Discontinued Products, H2 2017 30

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 14

Number of Products by Stage and Routes of Administration, H2 2017 14

Number of Products by Stage and Molecule Type, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports